It is intriguing that tumors with BRCA mutations are more likely to be HER2-negative49, implying that high activity of CDK12 in the HER2 amplicon in HER2-positive breast cancers maintains BRCA function and genome stability during tumor development. Here, CDK12 is linked to breast cancer.